EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-treatment direct costs for people with tuberculosis during the COVID-19 pandemic in different healthcare settings in Bandung, Indonesia

Bony Wiem Lestari iD, Eka Saptiningrum, Lavanya Huria, Auliya Ramanda Fikri iD, Benjamin Daniels, Nathaly Aguilera Vasquez, Angelina Sassi iD, Jishnu Das, Charity Oga-Omenka iD, Susan M McAllister, Madhukar Pai, Bachti Alisjahbana iD

PLOS ONE · 01.04.2025 · 20 (4) · e0320401

DOI: 10.1371/journal.pone.0320401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 01.04.2025. Verfasst von Bony Wiem Lestari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tuberculosis Working Group, Research Center for Care and Control of Infectious Disease Universitas Padjadjaran, Bandung, Indonesia. Hauptthemen laut MEDLINE: COVID-19, Tuberculosis, Health Care Costs, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tuberculosis (TB) program was massively disrupted due to the COVID-19 pandemic, which may have impacted on an increase in costs for people with TB (PWTB) and their households. We aimed to quantify the pre-treatment out-of-pocket costs and the factors associated with these costs from patients’ perspective during the COVID-19 pandemic in Bandung, Indonesia. Adults with pulmonary TB were interviewed using a structured questionnaire for this cross-sectional study recruiting from 7 hospitals, 59 private practitioners, and 10 community health centers (CHCs) between July 2021 to February 2022. Costs in rupiah were converted into US dollars and presented as a median and interquartile range (IQR). Factors associated with costs were identified using quantile regression. A total of 252 participants were recruited. The median total pre-treatment cost was $35.45 (IQR 17.69-67.62). The highest median cost was experienced by participants from private hospitals ($54.51, IQR 29.48-98.47). The rapid antigen and PCR for SARS-CoV-2 emerged as additional medical costs among 26% of participants recruited in private hospitals. Visiting ≥ 6 providers before diagnosis ($38.40 versus $26.20, p < 0.001), presenting first at a private hospital ($50.68, p < 0.05) and private practitioners ($34.97, p < 0.05), and being diagnosed in the private health sector ($39.98 versus $20.30, p < 0.05) were significantly associated with higher pre-treatment costs. PWTB experienced substantial out-of-pocket costs in the process of diagnosis during the COVID-19 pandemic despite free TB diagnosis and treatment. Early detection and identification play an important role in reducing pre-diagnostic TB costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19TuberculosisHealth Care CostsTuberculosis, PulmonaryHumansIndonesiaFemaleMaleAdultMiddle AgedCross-Sectional StudiesSARS-CoV-2Health ExpendituresPandemicsAged

Autor:innen und Institutionen

  • Tuberculosis Working Group, Research Center for Care and Control of Infectious Disease Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
  • McGill International TB Center, Montreal, Canada.
  • McCourt School of Public Policy, Georgetown University, Washington, District of Columbia, United States of America.

ORCID-Profile: Bony Wiem Lestari, Auliya Ramanda Fikri, Angelina Sassi, Charity Oga-Omenka, Bachti Alisjahbana

Förderung

  • Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Lestari, B. W., Saptiningrum, E., Huria, L., Fikri, A. R., Daniels, B., Vasquez, N. A., Sassi, A., Das, J., Oga-Omenka, C., McAllister, S. M., Pai, M., & Alisjahbana, B. (2025). Pre-treatment direct costs for people with tuberculosis during the COVID-19 pandemic in different healthcare settings in Bandung, Indonesia. PLOS ONE, 20(4), e0320401. https://doi.org/10.1371/journal.pone.0320401

Vancouver

Lestari BW, Saptiningrum E, Huria L, Fikri AR, Daniels B, Vasquez NA, et al. Pre-treatment direct costs for people with tuberculosis during the COVID-19 pandemic in different healthcare settings in Bandung, Indonesia. PLOS ONE. 2025;20(4):e0320401. doi:10.1371/journal.pone.0320401

BibTeX
@article{Lestari2025,
  author = {Lestari, Bony Wiem and Saptiningrum, Eka and Huria, Lavanya and Fikri, Auliya Ramanda and Daniels, Benjamin and Vasquez, Nathaly Aguilera and Sassi, Angelina and Das, Jishnu and Oga-Omenka, Charity and McAllister, Susan M and Pai, Madhukar and Alisjahbana, Bachti},
  title = {Pre-treatment direct costs for people with tuberculosis during the COVID-19 pandemic in different healthcare settings in Bandung, Indonesia},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {e0320401},
  doi = {10.1371/journal.pone.0320401}
}
Kostenlos starten →